Financial Performance - The company reported a loss per share of (3.59) HKD for the six months ended September 30, 2024, correcting a previous figure of (3.54) HKD[4] - The weighted average number of ordinary shares used for calculating the basic loss per share is 484,249, not 491,645 as previously stated[12] Financial Reporting Accuracy - The company clarified that the financial period descriptions in the interim results announcement should refer to the six months ended September 30, 2024, rather than June 30, 2024[10] - The company has acknowledged the errors in the interim results announcement and has made necessary clarifications to ensure accuracy[10] - The company will ensure that all future announcements maintain accuracy and clarity in financial reporting[8] Regulatory Compliance - The financial statements for the six months ended September 30, 2024, will be included in the interim report, which will be published in accordance with listing rules[8] - The company is committed to adhering to the listing rules and providing timely disclosures to stakeholders[8] - The interim report will be published in a timely manner as per regulatory requirements[8] Governance Structure - The board of directors includes three executive directors and three independent non-executive directors, ensuring a diverse governance structure[13] Interim Results Summary - The interim results announcement includes a summary of comprehensive income and other comprehensive income for the specified period[3]
中国卫生集团(00673) - 2025 - 中期业绩